These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 12427205)

  • 1. Outcomes in lower respiratory tract infections and the impact of antimicrobial drug resistance.
    Metlay JP; Singer DE
    Clin Microbiol Infect; 2002; 8 Suppl 2():1-11. PubMed ID: 12427205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on community-acquired pneumonia: impact of antibiotic resistance on clinical outcomes.
    Metlay JP
    Curr Opin Infect Dis; 2002 Apr; 15(2):163-7. PubMed ID: 11964918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment.
    Pfaller MA; Ehrhardt AF; Jones RN
    Am J Med; 2001 Dec; 111 Suppl 9A():4S-12S; discussion 36S-38S. PubMed ID: 11755437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and economic implications of antimicrobial resistance for the management of community-acquired respiratory tract infections.
    Nicolau D
    J Antimicrob Chemother; 2002 Sep; 50 Suppl S1():61-70. PubMed ID: 12239229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemifloxacin: a new, potent fluoroquinolone for the therapy of lower respiratory tract infections.
    File TM; Tillotson GS
    Expert Rev Anti Infect Ther; 2004 Dec; 2(6):831-43. PubMed ID: 15566328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hidden epidemic of macrolide-resistant pneumococci.
    Klugman KP; Lonks JR
    Emerg Infect Dis; 2005 Jun; 11(6):802-7. PubMed ID: 15963272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Streptococcus pneumoniae: does antimicrobial resistance matter?
    Lynch JP; Zhanel GG
    Semin Respir Crit Care Med; 2009 Apr; 30(2):210-38. PubMed ID: 19296420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance Program.
    Gordon KA; Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2003 Aug; 46(4):285-9. PubMed ID: 12944021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and economic outcomes in the treatment of lower respiratory tract infections.
    Brixner DI
    Am J Manag Care; 2004 Oct; 10(12 Suppl):S400-7. PubMed ID: 15603249
    [No Abstract]   [Full Text] [Related]  

  • 10. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic implications of macrolide resistance in pneumococcal community-acquired lower respiratory tract infections.
    Marrie TJ
    Int J Clin Pract; 2004 Aug; 58(8):769-76. PubMed ID: 15372850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia.
    Feldman C
    J Lab Clin Med; 2004 May; 143(5):269-83. PubMed ID: 15122171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Why do we need to eradicate pathogens in respiratory tract infections?
    Garau J
    Int J Infect Dis; 2003 Mar; 7 Suppl 1():S5-12. PubMed ID: 12839702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
    Jones RN; Fritsche TR; Sader HS
    Diagn Microbiol Infect Dis; 2005 Jun; 52(2):129-33. PubMed ID: 15964501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary care challenges in the management of respiratory tract infections.
    JAAPA; 2006 Sep; Suppl():4-14; quiz 15-6. PubMed ID: 17001773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug treatment of pneumococcal pneumonia in the elderly.
    Neralla S; Meyer KC
    Drugs Aging; 2004; 21(13):851-64. PubMed ID: 15493950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group.
    Heffelfinger JD; Dowell SF; Jorgensen JH; Klugman KP; Mabry LR; Musher DM; Plouffe JF; Rakowsky A; Schuchat A; Whitney CG
    Arch Intern Med; 2000 May; 160(10):1399-408. PubMed ID: 10826451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel agents for the treatment of outpatient respiratory tract infections. Introduction.
    Pell DM
    Postgrad Med; 2002 Sep; 112(3 Suppl):5-6. PubMed ID: 19667592
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical impact of antibiotic resistance in respiratory tract infections.
    Klugman KP
    Int J Antimicrob Agents; 2007 Feb; 29 Suppl 1():S6-10. PubMed ID: 17307654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Barriers to the effective management of respiratory tract infections in the community.
    Saginur R
    Infection; 2001 Dec; 29 Suppl 2():3-10. PubMed ID: 11785853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.